Showing 5011-5020 of 5771 results for "".
- Konan Medical’s EyeKinetix Pupillograph is Now Available in the United Stateshttps://modernod.com/news/konan-medicals-eyekinetix-pupillograph-is-now-available-in-the-united-states/2476902/Konan Medical announced that EyeKinetix is FDA listed and now available for sale in the United States. EyeKinetix is Konan’s 2nd generation pupillograph, which is smaller, faster, easier to use and less expensive than its predecessor, RAPDx, a device that brought key pupillary testin
- Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to DME or RVOhttps://modernod.com/news/graybug-vision-initiates-clinical-trial-in-macular-edema-secondary-to-dme-or-rvo/2476898/Graybug Vision announced the initiation of its phase 2a study with GB-102 in patients with macular edema (ME) secondary to diabetic macular edema (DME) or retinal vein occlusion (RVO). GB-102, a pan-Vascular Endothelial Growth Factor (VEGF) inhibitor and potential twice-per-year therapy is
- Oyster Point Pharma Expands Executive Leadership Teamhttps://modernod.com/news/oyster-point-pharma-expands-executive-leadership-team/2476896/Oyster Point Pharma announced the appointment of Dan Lochner, MBA, as its Chief Financial Officer, and John Snisarenko, MBA, as Chief Commercial Officer. Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset mana
- Aerie Pharmaceuticals Submits Prior Approval Supplement to FDA to Allow Production of Rocklatan in its Athlone Ireland Facilityhttps://modernod.com/news/aerie-pharmaceuticals-submits-prior-approval-supplement-to-fda-to-allow-production-of-rocklatan-in-its-athlone-ireland-facility/2476897/Aerie Pharmaceuticals announced the submission of a prior approval supplement (PAS) to the FDA to permit production of Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for sale in the United States in Aerie’s new manufacturing plant in Athlone, Ireland. “Along with t
- First International MIGS Data for the Omni Surgical System Presented at ESCRShttps://modernod.com/news/first-international-migs-data-for-the-omni-surgical-system-presented-at-escrs/2476893/Sight Sciences announced clinical results from the first study of the Omni Surgical System in glaucoma patients were presented at the European Society of Cataract and Refractive Surgery (ESCRS). Findings from the pilot study suggest the Omni Surgical System, which is dually indicated in
- Phase 2 Study Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to AMDhttps://modernod.com/news/phase-2-study-highlights-efficacy-and-safety-data-of-intravitreal-apl-2-for-geographic-atrophy-secondary-to-amd/2476891/Apellis Pharmaceuticals announced details about its phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) have been published in Ophth
- Zeiss and IDOC Partner to Bring Medical and Vision Care Products to Independent Optometrists Nationwidehttps://modernod.com/news/zeiss-and-idoc-partner-to-bring-medical-and-vision-care-products-to-independent-optometrists-nationwide/2476890/IDOC, Zeiss Vision Care US and Zeiss Medical Technology announced a 5-year agreement to bring Zeiss’ lab services, lens products and medical equipment to all 3,000+ IDOC independent optometrists across the United Stat
- Canon Xephilio OCT-A1 Device Receives FDA 510(k) Clearancehttps://modernod.com/news/canon-xephilio-oct-a1-device-receives-fda-510k-clearance/2476889/Expanding the company’s lineup of eye care product offerings, Canon USA announced the new intuitive Xephilio OCT-A1 device. This device features automated acquisition functionality, which makes it easy to use, allowing healthcare professionals to obtain high
- Johnson & Johnson Vision Introduces Tecnis Synergy IOLhttps://modernod.com/news/johnson-johnson-vision-introduces-tecnis-synergy-iol/2476884/Johnson & Johnson Vision announced the availability of the Tecnis Synergy IOL for patients in Europe, Australia, and New Zealand. The Tecnis Synergy IOL creates a new standard in presbyopia-correcting IOL (PC-IOL) technology, allowing patients to experience continuous high-contrast vision fro
- Candida Auris Tied to Vision Loss in Case Reporthttps://modernod.com/news/candida-auris-tied-to-vision-loss-in-case-report/2476883/Infection with Candida auris likely led to panophthalmitis and vision loss in an immune compromised patient, according to a case report published online today in the Annals of Internal Medicine, as